Proposals that are incomplete or received after the deadline will not be considered. All ESA Annual Meeting proposal and abstract deadlines are 5:00 PM Eastern so that technical support and ESA staff ...

The Hopkins Center for Health Disparities Solutions (HCHDS) at the Johns Hopkins Bloomberg School of Public Health is now accepting abstracts for poster presentations at the fourth annual HCHDS ...

TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

Submissions that are incomplete or received after the deadline will not be considered. All ESA Annual Meeting proposal and abstract deadlines are 5:00 PM Eastern so that technical support and ESA ...

CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today ...

CHICAGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...

LONG BEACH, Calif.--(BUSINESS WIRE)--The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, announced today that a video poster abstract presentation on the efficacy and safety ...

For more and to view the abstract, visit the AACR Annual Meeting website. As previously announced, on December 11, 2024, TuHURA entered into a definitive agreement with Kineta, Inc. (OTC Pink: KANT) ( ...

One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical trial of CAN-2409 plus standard of care chemoradiation ...

Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- Purple ...